The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells

The PI3Kδ-inhibitor Idelalisib is approved for the treatment of Non-Hodgkin lymphoma. However, its use has been decreased within the last years due to deleterious infections such as cytomegalovirus and pneumocystis jirovecii. Here, we have investigated the effect of Idelalisib on human monocyte-deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Christiane, Schlaweck, Sebastian, Daecke, Solveig Nora, Brossart, Peter, Heine, Annkristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571156/
https://www.ncbi.nlm.nih.gov/pubmed/34173009
http://dx.doi.org/10.1007/s00262-021-02988-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571156/
https://www.ncbi.nlm.nih.gov/pubmed/34173009
http://dx.doi.org/10.1007/s00262-021-02988-3

Ejemplares similares